Growth Centered on Automotive-Related Markets and Expansion into Healthcare, Infrastructure, and Housing Equipment Markets
First written in FY2017. 7 of 15 entries say "Advanced", first in FY2021. Latest entry: FY2026.
The whole theme swung hardest in 2025: 5 of 24 companies on the "Worse" side.
7 other companies' latest entry also says "Restated".
- FY2026RestatedAnnual report
「In Japan, we will expand orders for cutting-edge, high-value-added products addressing themes such as next-generation EVs and HEVs, CASE (Connected, Autonomous, Sharing and Electric) and comfort.」
The company continues its policy of keeping the automotive market as its core, targeting next-generation EVs and HEVs, CASE and comfort in Japan, and megasuppliers and localized products overseas for transaction expansion. - FY2025RestatedAnnual report
「In Japan, we will expand orders for cutting-edge, high-value-added products addressing next-generation EVs and HEVs, as well as themes such as CASE (Connected, Autonomous, Sharing and Electric) and comfort. Overseas, we will highlight our global supply system to major automotive-parts manufacturers known as megasuppliers and use this to expand transactions.」
The company continues its policy of keeping the automotive market as its core, targeting EVs, HEVs, CASE and comfort in Japan and megasuppliers overseas for transaction expansion. - FY2025-H1RestatedAnnual report
「We operate in Japan, the Americas, Europe and 12 Asian countries, primarily manufacturing and selling metal components, including precision springs, for the automotive, medical, office automation and aircraft markets.」
The company continues to describe its global operations focused on the automotive, medical, office automation and aircraft markets. It separately explains that the medical business is expanding steadily while automotive demand remains sluggish during the interim period. - FY2024RaisedAnnual report
「In Japan, we will expand orders for cutting-edge, high-value-added products addressing CASE (connected, autonomous, shared and electric mobility) and comfort, as well as next-generation vehicles. Overseas, in addition to products related to "CASE plus comfort" as in Japan, we will seek to expand transaction volumes by highlighting our global supply system to major automotive-parts manufacturers known as megasuppliers.」
The automotive growth strategy has been made more specific and expanded to include high-value-added products related to CASE and comfort, overseas megasuppliers and expanded transactions with Chinese automotive-parts manufacturers. - FY2024-Q3AdvancedAnnual report
「As production launches for automotive and medical applications progressed at the U.S. and Mexico plants, net sales increased 52.5% year on year to ¥3,182 million.」
Production launches for automotive and medical applications progressed at the U.S. and Mexico plants, and sales in the Americas increased 52.5% year on year. - FY2024-Q2AdvancedAnnual report
「As production launches for automotive and medical applications progressed at the U.S. and Mexico plants, net sales increased 58.0% year on year to ¥2,162 million.」
Production launches for automotive and medical applications progressed at the U.S. and Mexico plants, and sales in the Americas increased 58.0% year on year. This indicates specific progress in the policy of developing the medical market while keeping automotive as the core business. - FY2022AdvancedAnnual report
「The medical business is one we intend to strengthen further because its contribution to earnings is expected to remain stable, given projections that the number of middle- and high-income people who will benefit from advanced medical care worldwide will double over the next 15 years, the progress of global approvals for drug kits incorporating our spring products, and the outlook for low-volatility, long-term growth.」
The company specified the projected increase in middle- and high-income populations, progress in drug-kit approvals and the use of its global supply system for megapharmaceutical companies as the basis for and measures supporting growth in the medical business. - FY2022-Q1AdvancedAnnual report
「Demand recovered broadly, including for automotive and office automation equipment. Net sales increased 36.2% year on year to ¥2,152 million, and segment profit was ¥121 million, compared with a loss of ¥131 million in the same quarter of the previous year.」
Demand in Japan, including automotive and office automation equipment, recovered, and segment profit turned around from a loss in the same period of the previous year to a profit of ¥121 million. - FY2021AdvancedAnnual report
「In the fiscal year ending March 2021, there were encouraging developments, particularly in Europe and the Americas, including inquiries from major global pharmaceutical companies. In Japan, an innovative project themed around "quality of life" has also begun.」
In addition to its growth strategy centered on the automotive market, the company described inquiries from major pharmaceutical companies for its medical business and the launch of a new project in Japan, indicating progress in developing the medical market. - FY2020RaisedAnnual report
「In Japan, we will expand orders for cutting-edge products, including those for core components of electric vehicles (EVs). Overseas, we will seek to increase transaction volumes by highlighting our global supply system to major automotive-parts manufacturers known as megasuppliers.」
The company made its growth strategy centered on the automotive market more specific, targeting EV core components in Japan and megasuppliers overseas and setting out ways to expand transactions. - FY2018RaisedAnnual report
「We will pursue growth opportunities in the automotive market, which accounts for most spring demand, and seek to expand transactions with Japanese and European and U.S. parts manufacturers. In Japan, we are bringing forward the expansion of our dedicated automotive-parts plant in Saitama to respond to strong orders.」
The company continues its policy of expanding transactions with automotive-parts manufacturers and states that the Saitama plant expansion will proceed ahead of the previous schedule. - FY2017First statedAnnual report
「We will pursue growth opportunities in the automotive market, which accounts for most spring demand, and seek to expand transactions with Japanese and European and U.S. parts manufacturers. In Japan, we plan to bring the Saitama plant into full operation and, in 2019, expand the plant to meet strong orders. We will also strengthen sales to the medical-device and infrastructure and residential-equipment markets with the aim of establishing a third pillar after automotive and office automation equipment.」
The company has for the first time consolidated a policy of making the automotive market its core market, proceeding with the full-scale operation and 2019 expansion of the Saitama plant, and developing medical devices and infrastructure and residential equipment as a third pillar.